Stockscreener 앱 받기
1.04
4.59%
-0.05
시간 외 거래:
1.06
0.02
+1.92%
전일 마감가:
$1.09
열려 있는:
$1.07
하루 거래량:
311.84K
Relative Volume:
0.43
시가총액:
$107.33M
수익:
$32.29M
순이익/손실:
$-39.12M
주가수익비율:
-2.8346
EPS:
-0.3669
순현금흐름:
$-29.51M
1주 성능:
-7.14%
1개월 성능:
-18.75%
6개월 성능:
+46.48%
1년 성능:
-32.90%
1일 변동 폭
$1.04
$1.08
1주일 범위
$1.04
$1.16
52주 변동 폭
$0.6434
$1.865
맥스사이트 Stock (MXCT) Company Profile
명칭
Maxcyte Inc
전화
301-517-5556
주소
9713 KEY WEST AVENUE,, ROCKVILLE
Compare MXCT vs ABT, MDT, SYK, BSX, EW
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
MXCT
Maxcyte Inc
|
1.04 | 120.75M | 32.29M | -39.12M | -29.51M | -0.3669 |
ABT
Abbott Laboratories
|
98.73 | 168.71B | 46.59B | 5.41B | 7.38B | 3.0938 |
MDT
Medtronic Plc
|
85.51 | 110.49B | 36.36B | 4.84B | 5.43B | 3.7261 |
SYK
Stryker Corp
|
275.40 | 105.65B | 25.27B | 3.34B | 4.57B | 8.6334 |
BSX
Boston Scientific Corp
|
41.58 | 63.65B | 20.62B | 3.56B | 3.48B | 2.3847 |
EW
Edwards Lifesciences Corp
|
85.78 | 49.74B | 6.30B | 1.07B | 1.09B | 1.8406 |
맥스사이트 Stock (MXCT) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2025-08-11 | 다운그레이드 | BTIG Research | Buy → Neutral |
| 2025-08-07 | 다운그레이드 | William Blair | Outperform → Mkt Perform |
| 2025-07-22 | 개시 | Stephens | Overweight |
| 2023-11-29 | 개시 | Craig Hallum | Buy |
| 2021-10-15 | 재개 | Cowen | Outperform |
| 2021-08-24 | 개시 | BTIG Research | Buy |
| 2021-08-24 | 개시 | Cowen | Outperform |
| 2021-08-24 | 개시 | Stephens | Overweight |
| 2021-08-24 | 개시 | Stifel | Buy |
| 2021-08-24 | 개시 | Wedbush | Outperform |
| 2021-08-24 | 개시 | William Blair | Outperform |
모두보기
맥스사이트 주식(MXCT)의 최신 뉴스
North America Non-Viral Transfection Reagents Market Forecast to 2035 | Cell and Gene Therapy Demand Drives 8.5% CAGR and a USD 0.70 Billion Opportunity - GlobeNewswire Inc.
MaxCyte names Sidharth Kapileshwar as CCDO - Medical Buyer
MaxCyte stock slips 4.03 percent as new chief arrives - AD HOC NEWS
MaxCyte appoints Sidharth Kapileshwar as chief corporate officer By Investing.com - Investing.com Australia
MaxCyte appoints Sidharth Kapileshwar as chief corporate officer - Investing.com India
MaxCyte Names Sidharth Kapileshwar Chief Corporate Development Officer - citybiz
MaxCyte Appoints Sidharth Kapileshwar as Chief Corporate Development Officer - The Manila Times
MaxCyte's new executive has held strategy, innovation and M&A roles over nearly 25 years. - Stock Titan
MaxCyte stock falls as revenue and market value remain under pressure - AD HOC NEWS
MaxCyte stock edges higher as analysts stick to Strong Buy rating - AD HOC NEWS
MaxCyte Inc (MXCT) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
MaxCyte Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - The Manila Times
MaxCyte Reports Inducement Grants Under Nasdaq Listing Rule 5635(C)(4) - TradingView
MaxCyte Inc (NASDAQ: MXCT) Stock Price, News & Analysis - Kalkine
MXCT stock holds steady as MaxCyte focuses on cell-therapy growth - ad-hoc-news.de
MXCT stock holds steady as MaxCyte prepares next growth steps - ad-hoc-news.de
MXCT Q2 2026 Earnings: Narrower-Than-Expected Loss Lifts Shares 2.42%Share Dilution Risk - vinanet.vn
MaxCyte Inc. (MXCT) Shareholding Pattern – Promoters, FIIs & DIIs - Value Research
MaxCyte Inc. (MXCT) Peer Comparison – Compare with Others - valueresearchonline.com
MaxCyte stock rating held at Neutral by BTIG after Q2 results - Investing.com India
MaxCyte (MXCT) Q2 2026 Earnings: EPS Comes in Above Forecast in the Latest Reading; Market Reaction - vinanet.vn
MaxCyte Gets A Genentech Nod, But Revenue Still Comes In Chunks - Finimize
MaxCyte launches base editor off-target nomination assays By Investing.com - Investing.com Nigeria
MaxCyte (MXCT) Earnings Reading: EPS Prints Above Forecast in the Latest Session; Stock Move - vinanet.vn
MaxCyte launches base editor off-target nomination assays - Investing.com
MaxCyte launches CHANGE-seq-BE™ and ONE-seq-BE™ to strengthen off-target assessment for genome editing therapies - The Manila Times
MaxCyte launches a gene-editing test that sees population-specific DNA variants - Stock Titan
MaxCyte, Inc. Revenue Breakdown – NASDAQ:MXCT - TradingView
MaxCyte(MXCT) Stock Options Chain | Quotes & News - Moomoo
MXCT Q2 2026 Earnings: Narrower-Than-Expected Loss Marks a 15.97% EPS Beat, Yet Shares Slip 5.04%Earnings Sentiment Score - vinanet.vn
Teleconferência de Resultados do 2T26 da MaxCyte (MXCT): Guidance Reafirmado com a Expansão da Parceria com a Genentech - TradingKey
Conferencia de resultados del T2 de 2026 de MaxCyte (MXCT): Se reafirman las proyecciones a medida que se amplía la alianza con Genentech - TradingKey
MaxCyte, Inc. Releases Q2 2026 Results: Cell Engineering Platform Momentum in FocusRevenue Inflection Point - dars.gov.et
MaxCyte (MXCT) Earnings Call Q2 2026: Prognose bekräftigt bei Ausbau der Genentech-Partnerschaft - TradingKey
MaxCyte (MXCT) Q2 2026 Earnings Call: Guidance Reaffirmed as Genentech Partnership Expands - TradingKey
Stifel Nicolaus Keeps Their Buy Rating on MaxCyte (MXCT) - The Globe and Mail
TD Cowen Maintains MaxCyte(MXCT.US) With Buy Rating - Moomoo
MaxCyte revenue down 15% to USD 7.3M in Q2 2026 - medicalbuyer.co.in
MaxCyte, Inc. $MXCT Shares Acquired by Renaissance Technologies LLC - MarketBeat
Price to sales forward of MaxCyte, Inc. – MUN:MYE0 - TradingView
MaxCyte Reports Second Quarter 2026 Financial Results - The Manila Times
MaxCyte Inc (MXCT) (Q2 2026) Earnings Call Highlights: Strategic Pivot to Enterprise ... - Yahoo! Finance Canada
MXCT Looks 49.6% Undervalued on GF Value™ - GuruFocus
MaxCyte, Inc. Q2 2026 Earnings Call Summary - Yahoo Finance
MaxCyte Q2 Earnings Call Highlights - MarketBeat
MaxCyte (NASDAQ:MXCT) Issues Earnings Results - MarketBeat
MaxCyte affirms FY26 sales guidance of $30M-$32M vs estimate - scanx.trade
MaxCyte, Inc. (MXCT) Reports Q2 Loss, Beats Revenue Estimates - Yahoo Finance
Earnings call transcript: MaxCyte tops Q2 2026 revenue forecast, shares fall - Investing.com
MaxCyte Reports Q2 Results, Highlights Genentech Partnership - TipRanks
MaxCyte Inc reports results for the quarter ended June 30Earnings Summary - TradingView
맥스사이트 (MXCT) 재무 분석
매출
순이익
현금흐름
주당 순 이익
1.33%
0.49%
자본화:
|
볼륨(24시간):